Trial reportProceedings of the National Academy of Sciences of the United States of America2014
Induction of broadly cross-reactive antibody responses to the influenza HA stem region following H5N1 vaccination in humans.
Trial report in Proceedings of the National Academy of Sciences of the United States of America, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 167 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
167 citing papers in PubMed.
- Exogenous melatonin boosts vaccine-induced immunity in individuals with high pre-existing influenza immunity.Frontiers in immunology · 2025Trial
- Safety and immunogenicity of a ferritin nanoparticle H2 influenza vaccine in healthy adults: a phase 1 trial.Nature medicine · 2022Trial
- A chimeric hemagglutinin-based universal influenza virus vaccine approach induces broad and long-lasting immunity in a randomized, placebo-controlled phase I trial.Nature medicine · 2021Trial
- Matrix M Adjuvanted H5N1 Vaccine Elicits Broadly Neutralizing Antibodies and Neuraminidase Inhibiting Antibodies in Humans That Correlate WithFrontiers in immunology · 2021Trial
- Subdominance and poor intrinsic immunogenicity limit humoral immunity targeting influenza HA stem.The Journal of clinical investigation · 2019Trial
- High-Affinity H7 Head and Stalk Domain-Specific Antibody Responses to an Inactivated Influenza H7N7 Vaccine After Priming With Live Attenuated Influenza Vaccine.The Journal of infectious diseases · 2015Trial
- Single dose vaccination of the ASO3-adjuvanted A(H1N1)pdm09 monovalent vaccine in health care workers elicits homologous and cross-reactive cellular and humoral responses to H1N1 strains.Human vaccines & immunotherapeutics · 2015Trial
- Advances and challenges in avian influenza vaccines: From conventional approaches to next-generation strategies.Veterinary and animal science · 2026Review
- Article
- Repeated influenza vaccination results in blunting rather than back-boosting of antibody responses against A(H3N2) antigens.Research square · 2026Article
- Computational Design and Expression of Headless Influenza Hemagglutinin Antigens Toward a Modular Universal Nanoparticle Vaccine.Antibodies (Basel, Switzerland) · 2026Article
- Preclinical evaluation of an mRNA vaccine developed from the first human isolate of bovine H5N1.Cell reports. Medicine · 2026Article
- Article
- Epitope-spanning antigenic variation reprograms immunodominance and broadens immunity in sequential influenza vaccination.Nature communications · 2026Article
- An intranasal adenoviral-vectored vaccine protects against highly pathogenic avian influenza H5N1 in naive and antigen-experienced animals.Cell reports. Medicine · 2026Article
- Affinity maturation and light-chain-mediated paratope diversification anticipates viral evolution.Cell reports · 2026Article
- Delineation of the antibody light chain biases and kinetics following primary and secondary influenza virus infections of ferrets.ImmunoHorizons · 2026Article
- Common cold embecovirus imprinting primes broadly neutralizing antibody responses to SARS-CoV-2 S2.The Journal of experimental medicine · 2025Article
- Immunodominant antibodies against hemagglutinin in ferrets following infection with 2018 to 2019 influenza vaccine strains.NPJ vaccines · 2025Article
- Review
107 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
Abstract
The emergence of pandemic influenza viruses poses a major public health threat. Therefore, there is a need for a vaccine that can induce broadly cross-reactive antibodies that protect against seasonal as well as pandemic influenza strains. Human broadly neutralizing antibodies directed against highly conserved epitopes in the stem region of influenza virus HA have been recently characterized. However, it remains unknown what the baseline levels are of antibodies and memory B cells that are directed against these conserved epitopes. More importantly, it is also not known to what extent anti-HA stem B-cell responses get boosted in humans after seasonal influenza vaccination. In this study, we have addressed these two outstanding questions. Our data show that: (i) antibodies and memory B cells directed against the conserved HA stem region are prevalent in humans, but their levels are much lower than B-cell responses directed to variable epitopes in the HA head; (ii) current seasonal influenza vaccines are efficient in inducing B-cell responses to the variable HA head region but they fail to boost responses to the conserved HA stem region; and (iii) in striking contrast, immunization of humans with the avian influenza virus H5N1 induced broadly cross-reactive HA stem-specific antibodies. Taken together, our findings provide a potential vaccination strategy where heterologous influenza immunization could be used for increasing the levels of broadly neutralizing antibodies and for priming the human population to respond quickly to emerging pandemic influenza threats.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.